Press Releases.

Month Year

Month Year

Investor Alerts

June 02, 2022

Regulus Appoints Amin Kamel, Ph.D., as Vice President, DMPK
May 17, 2022

Regulus Therapeutics to Present at the H.C. Wainwright Global Investment Conference
May 12, 2022

Regulus Therapeutics Reports First Quarter 2022 Financial Results and Recent Updates
May 11, 2022

Regulus Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
May 05, 2022

Regulus Therapeutics Announces Timing for First Quarter 2022 Financial Results Webcast and Conference Call
March 24, 2022

Regulus Therapeutics Announces Initiation of Preclinical Studies in Amyotrophic Lateral Sclerosis under a Collaboration Agreement with Harvard's Brigham and Women's Hospital
March 10, 2022

Regulus Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Recent Updates
March 03, 2022

Regulus Therapeutics Announces Timing for Fourth Quarter and Year-End 2021 Financial Results Webcast and Conference Call
February 24, 2022

Regulus Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Lademirsen for Alport Syndrome

--Final data and potential for $25m milestone anticipated in H1 2023--
February 10, 2022

Regulus Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Show per page